文献速递胸部肿瘤

阿维鲁单抗对比铂类双药化疗一线治疗高表达程序性死亡配体1阳性转移性非小细胞肺癌:3期JAVELIN Lung 100试验主要分析

Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
PubMed 文献 · J Thorac Oncol · 2023-09-24

JAVELIN Lung 100是一项3期试验,比较阿维鲁单抗与铂类双药化疗一线治疗PD-L1阳性晚期非小细胞肺癌。在高表达PD-L1(≥80%肿瘤细胞)人群中,阿维鲁单抗Q2W组对比化疗的OS HR为0.85(95%CI 0.67-1.09;单侧p=0.1032),PFS HR为0.71(95%CI 0.54-0.93;单侧p=0.0070);QW组对比化疗的OS HR为0.79(95%CI 0.59-1.07;单侧p=0.0630),PFS HR为0.72(95%CI 0.52-0.98;单侧p=0.0196)。差异未达统计学显著,试验未达到主要目标。

要点

  • 高表达PD-L1(≥80%)人群中,阿维鲁单抗Q2W组中位OS 20.1个月 vs 化疗组14.9个月,HR 0.85(95%CI 0.67-1.09;单侧p=0.1032)。
  • 高表达PD-L1人群中,阿维鲁单抗Q2W组中位PFS 8.4个月 vs 化疗组5.6个月,HR 0.71(95%CI 0.54-0.93;单侧p=0.0070)。
  • 阿维鲁单抗QW组对比化疗组中位OS 19.3 vs 15.3个月(HR 0.79;95%CI 0.59-1.07;单侧p=0.0630),中位PFS 7.5 vs 5.6个月(HR 0.72;95%CI 0.52-0.98;单侧p=0.0196)。

核心结论

  • 在高表达PD-L1阳性晚期非小细胞肺癌中,阿维鲁单抗对比铂类双药化疗观察到更长的中位OS和PFS,但OS和PFS差异未达统计学显著,试验未达到主要目标。

研究设计与样本

  • 3期JAVELIN Lung 100试验(NCT02576574),纳入PD-L1阳性(≥1%肿瘤细胞;PD-L1免疫组化73-10 pharmDx)、EGFR和ALK野生型、既往未治疗的IV期非小细胞肺癌成人患者。
  • 共1214例患者随机分配至阿维鲁单抗10 mg/kg每2周(Q2W,n=366)、阿维鲁单抗10 mg/kg每周(QW)12周后改为每2周(n=322)或铂类双药化疗每3周(n=526)。
  • 主要分析人群为高表达PD-L1阳性肿瘤患者(≥80%肿瘤细胞),主要终点为独立审查委员会评估的总生存期(OS)和无进展生存期(PFS)。

主要发现

  • 高表达PD-L1人群中,阿维鲁单抗Q2W组(n=151)对比化疗组(n=216)的OS HR为0.85(95%CI 0.67-1.09;单侧p=0.1032),中位OS 20.1 vs 14.9个月。
  • 高表达PD-L1人群中,阿维鲁单抗Q2W组对比化疗组的PFS HR为0.71(95%CI 0.54-0.93;单侧p=0.0070),中位PFS 8.4 vs 5.6个月。
  • 高表达PD-L1人群中,阿维鲁单抗QW组(n=130)对比化疗组(n=129)的OS HR为0.79(95%CI 0.59-1.07;单侧p=0.0630),中位OS 19.3 vs 15.3个月。
  • 高表达PD-L1人群中,阿维鲁单抗QW组对比化疗组的PFS HR为0.72(95%CI 0.52-0.98;单侧p=0.0196),中位PFS 7.5 vs 5.6个月。
  • 未观察到新的安全性信号。

关键数值与推荐

  • PD-L1阳性定义为≥1%肿瘤细胞,采用PD-L1免疫组化73-10 pharmDx检测。
  • 高表达PD-L1阳性定义为≥80%肿瘤细胞。
  • 阿维鲁单抗给药方案:10 mg/kg每2周;或10 mg/kg每周12周后改为每2周。
  • 化疗方案为铂类双药化疗每3周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We report the primary analysis from JAVELIN Lung 100, a phase 3 trial comparing avelumab (anti-programmed death-ligand 1 [PD-L1]) versus platinum-based doublet chemotherapy as first-line treatment for PD-L1-positive (+) advanced NSCLC. METHODS: Adults with PD-L1+ (≥1% of tumor cells; PD-L1 immunohistochemistry 73-10 pharmDx), EGFR and ALK wild-type, previously untreated, stage IV NSCLC were randomized to avelumab 10 mg/kg every 2 weeks (Q2W), avelumab 10 mg/kg once weekly (QW) for 12 weeks and Q2W thereafter, or platinum-based doublet chemotherapy every 3 weeks. Primary end points were overall survival (OS) and progression-free survival (PFS) per independent review committee. The primary analysis population was patients with high-expression PD-L1+ tumors (≥80% of tumor cells). RESULTS: A total of 1214 patients were randomized to avelumab Q2W (n = 366), avelumab QW (n = 322), or chemotherapy (n = 526). In the primary analysis population, hazard ratios (HRs) for OS and PFS with avelumab Q2W (n = 151) versus chemotherapy (n = 216) were 0.85 (95% confidence interval [CI]: 0.67-1.09; one-sided p = 0.1032; median OS, 20.1 versus 14.9 mo) and 0.71 (95% CI: 0.54-0.93; one-sided p = 0.0070; median PFS, 8.4 versus 5.6 mo), respectively. With avelumab QW (n = 130) versus chemotherapy (n = 129), HRs were 0.79 (95% CI: 0.59-1.07; one-sided p = 0.0630; median OS, 19.3 versus 15.3 mo) and 0.72 (95% CI: 0.52-0.98; one-sided p = 0.0196; median PFS, 7.5 versus 5.6 mo), respectively. No new safety signals were observed. CONCLUSIONS: Longer median OS and PFS were observed with avelumab versus platinum-based doublet chemotherapy in advanced NSCLC, but differences in OS and PFS were not statistically significant, and the trial did not meet its primary objective. CLINICALTRIALS: gov Identifier: NCT02576574.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Reck M, Barlesi F, Yang JC, et al. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial. J Thorac Oncol. 2023. PMID: 37748693. doi:10.1016/j.jtho.2023.09.1445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。